

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

SEP 10 2007

(use as many sheets as necessary)

Trade Sheet

1

of

2

COMPLETE IF KNOWN

Application Number	10/550,968
---------------------------	-------------------

Filing Date	September 26, 2005
--------------------	---------------------------

First Named Inventor	Mark E. Duggan
-----------------------------	----------------

Group Art Unit	1621
----------------	------

Examiner Name	S. Kumar
---------------	----------

Attorney Docket Number 21298P

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

S. Kummer

Date Considered

9/21/07

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/550,968	
			Filing Date	September 26, 2005	
			First Named Inventor	Mark E. Duggan	
			Group Art Unit	1621	
			Examiner Name		
Sheet	2	of	2	Attorney Docket Number	21298P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
AK		Chemical Abstracts Service, Columbus Ohio, US; XP002438782, retrieved from STN Accession No. 1962:12809, Database Accession No. 56:12809, RNs: 93323-83-2 and 98742-49-5.
		J. A. O'Brien et al., "A Novel Selective Allosteric Modulator Potentiates the Activity of Native Metabotropic Glutamate Receptor Subtype 5 in Rat Forebrain" J. of Pharmacology and Experimental Therapeutics, 2004, Vol. 309, No. 2, pgs. 568-577.
		Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002438783, Database Accession No. BRN:3376420.
		Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002438784, Database Accession No. BRN:344532.
		Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002438785, Database Accession No. BRN:3461782.
		Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002438786, Database Accession No. BRN:2731365.
AK		Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002438787, Database Accession No. BRN:2809287.

Examiner Signature	S. Kumar	Date Considered	9/21/07
--------------------	----------	-----------------	---------

(use as many sheets as necessary)

Sheet

1

of

1

Application Numbers

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

COMPLETE IF KNOWN

10/550968

er JC09 Rec'd PCT/PTC 26 SEP 2005

September 26, 2005

Mark E. Duggan, et al.

1691

S. Kumar

21298P

Examiner
Initials*Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

8c

MANO, P. De, et al, The constitution of isamic acid, Canadian Journal of Chemistry, 1967, Vol 45, pages 2177-2190.

ge

ROSEVEAR, J. et al, A comparison of the reactions of some Ethyl N-Arylcarbamates with Those of the Corresponding Acetanilides. II* Amidomethylation with N-Hydroxymethylphthalimide, Australian Journal of Chemistry, 1990, Vol 43, No. 2, pages 339-53.

82

BEDDOES, R. L., et al, Synthesis of 2,3,5,6-Tetrahydro-1H, 4H, 11CH-3a,6a, 11b-TRIAZBENZ(de) ANTHRACENE (5) AND X-RAY CRYSTAL STRUCTURE DETERMINATION OF (5), HEXAHYDRO-1H,4H,7H,9bH-3a,6a,9a-TRIAZAPHENALENE (1), BENZO(B)-1,5,9-TRIAZADODECANE, N,N,N"-TRITOSYLAMIDE, AND OF 1,5,9, TRIAZADOODECANE N,N,N"-TRITOSYLAMIDE, *Tetrahedron*, 1987, Vol 43, No. 8, pages 1903-1920.

**Examiner
Signature**

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc. -7/12/2005